Santos Gonzalez F, Martin E, Harris M, Casauria S, The Australian Undiagnosed Disease Network, Christodoulou J, Goranitis I. The value of functional genomics: a contingent valuation. Expert Rev Pharmacoecon Outcomes Res. 2026 Feb;26(2):195-202.
Liu C, Best S, Fatkin D, Goranitis I. Societal Preferences, Values and Priorities for Genomic Testing for Atrial Fibrillation: Evidence from Two Discrete Choice Experiments. Patient. 2026 Feb 13.
Fehlberg Z, Liu C, Kugenthiran N, Fatkin D, Goranitis I, Best S. Gauging Patient- and Family-Perceived Value of Genetic Testing for Atrial Fibrillation. Heart, Lung and Circulation. 2026;35(3):e29-e31.
2025
Rius R, Compton AG, … Goranitis I, … Thorburn DR. The Australian Genomics Mitochondrial Flagship: A national program delivering mitochondrial diagnoses. Genetics in Medicine. 2025;27(1).
Fehlberg, Z., Fisher, L., Liu, C., Kugenthiran, N., Milne, R. L., Young, M. A., ... & Best, S. (2025). Using a behaviour-change approach to support uptake of population genomic screening and management options for breast or prostate cancer. European Journal of Human Genetics, 33(1), 108-120.
Kelada L, Best S, Pierce K, … Goranitis I, … Howell KB. Fulfilling the needs of caregivers in delivering health services to children with developmental and epileptic encephalopathies. European Journal of Paediatric Neurology. 2025;54:147-58.
Santos Gonzalez F, Ungar WJ, … Goranitis I. Microcosting genomics: Challenges and opportunities. Genetics in Medicine. 2025;27(2).
Goranitis I, Sheen D, Fehlberg Z, Mallett AJ, Best S, Stark Z. A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale. Value in Health. 2025;28(2):184-90.
Schilling C, Sjaaf F, Goranitis I, …, Gaff C. Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023. European Journal of Human Genetics. 2025.
Best S, Braithwaite J, Goranitis I, ... Using implementation science to navigate the complexity of integrating genomics into healthcare. Nature Medicine. 2025.
Bourke M, McInerney-Leo A, …, Goranitis I. The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review. Applied Health Economics and Health Policy. 2025.
Buchanan J, Goranitis I, Weymann D. The Health Economics of Genomic Technologies: A Growing Evidence Base on Value. Appl Health Econ Health Policy. 2025;23(3):331-5.
Smith HS, Buchanan J, Goranitis I, et al. Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity. Value in Health. 2025;28(8):1213-20
Smith HS, Regier DA, Goranitis I, … Marshall DA. Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework. Applied Health Economics and Health Policy. 2025.
Peters R, Best S...Goranitis I. Public preferences for the value and implementation of genomic newborn screening: Insights from two discrete choice experiments in Australia. The American Journal of Human Genetics.
Pan T, Trajanovska M... Goranitis I. Psychometric comparison of CHU9D and PedsQL 4.0 proxy version administered to parents of children with congenital colorectal conditions in Australia. The European Journal of Health Economics. 2025 DeBortoli E, McGahan E, Yanes T, Berkman J, Aoude LG, Smit AK, et al. Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer. Cancer Medicine. 2025;14(15):e71080.
Lunke S, Downie L, Caruana J, Kugenthiran N, De Fazio P, Hollizeck S, ... Goranitis I...et al. Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study. Nature Medicine. 2025. Sheen D, Willis A, Fehlberg Z, .. Gorantis I, MA Young. Systematic review of preferences for additional findings from genomic testing. Eur J Hum Genet. 2025
Goranitis I, Hayeems RZ, Smith HS, Buchanan J, Weymann D, Regier DA, et al. Determining the value of genomics in healthcare. Nature Medicine. 2025.
Pan T, Trajanoversuska M, Meng Y, Best S, King SK, Goranitis I. Public Preferences and Willingness to Pay for a Multidisciplinary Colorectal and Pelvic Reconstruction Service. The Patient - Patient-Centered Outcomes Research. 2025.
2024
Eratne D, Kang MJY, Lewis C, Dang C, Malpas C, Ooi S, et al. Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders. Journal of the Neurological Sciences. 2024;467:123291.
Park K, Chen M, Malijan GM, Song D, Ross AL, Ambrosino E, et al. Accelerating access to human genomics for public health: perspectives from the Western Pacific region. The Lancet Regional Health - Western Pacific. 2024;53.
Santos Gonzalez F, Hock DH, Thorburn DR, Mordaunt D, Williamson NA, Ang CS... Goranitis I. A micro-costing study of mass-spectrometry based quantitative proteomics testing applied to the diagnostic pipeline of mitochondrial and other rare disorders. Orphanet Journal of Rare Diseases. 2024;19(1).
Best S, Fehlberg Z, Richards C, Quinn MCJ, Lunke S, Spurdle AB, et al. Reanalysis of genomic data in rare disease: current practice and attitudes among Australian clinical and laboratory genetics services. European Journal of Human Genetics. 2024;32(11):1428-35.
Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E. A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist. PharmacoEconomics. 2024;42(10):1161-75.
Mallawaarachchi A, Biros E, Harris T, Bennetts B, Boughtwood T, Elliott J, et al. Shaping the future of kidney genetics in Australia: proceedings from the KidGen policy implementation workshop 2023. Human Genomics. 2024;18(1).
Williams EV, Goranitis I, Oppong R, Perry SJ, Devall AJ, Martin JT, et al. A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial. Nature Medicine. 2024;30(8):2343-8.
Fehlberg Z, Goranitis I, Mallett AJ, Stark Z, Best S. Determining priority indicators of utility for genomic testing in rare disease: A Delphi study. Genetics in Medicine. 2024;26(6).
Lynch F, Best S, Gaff C, Downie L, Archibald AD, Gyngell C, et al. Australian public perspectives on genomic newborn screening: which conditions should be included? Human Genomics. 2024;18(1).
Marshall DA, Hua N, Buchanan J, Christensen KD, Frederix GWJ, Goranitis I, et al. Paving the path for implementation of clinical genomic sequencing globally: Are we ready? Health Aff Sch. 2024;2(5):qxae053.
Lunke S, Bouffler SE, Downie L, Caruana J, Amor DJ, Archibald A, et al. Prospective cohort study of genomic newborn screening: BabyScreen+ pilot study protocol. BMJ Open. 2024;14(4).
Meng Y, Best S, Amor DJ, Braden R, Morgan AT, Goranitis I. The value of genomic testing in severe childhood speech disorders. European Journal of Human Genetics. 2024;32(4):440-7.
Mordaunt DA, Gonzalez FS, Lunke S, Eggers S, Sadedin S, Chong B,… Goranitis I. The cost of proband and trio exome and genome analysis in rare disease: A micro-costing study. Genetics in Medicine. 2024;26(4).
Lynch F, Meng Y, Best S, Goranitis I, Savulescu J, Gyngell C, Vears DF. Australian public perspectives on genomic data governance: responsibility, regulation, and logistical considerations. European Journal of Human Genetics. 2024;32(3):295-301.
Goranitis I, Meng Y, Martyn M, Best S, Bouffler S, Bombard Y, et al. Eliciting parental preferences and values for the return of additional findings from genomic sequencing. npj Genomic Medicine. 2024;9(1).
Robertson EG, Kelada L, Best S, Goranitis I, Pierce K, Roberts NJ, et al. Quality of life in caregivers of a child with a developmental and epileptic encephalopathy. Developmental Medicine and Child Neurology. 2024;66(2):206-15.
Lynch F, Best S, Gaff C, Downie L, Archibald AD, Gyngell C, et al. Australian Public Perspectives on Genomic Newborn Screening: Risks, Benefits, and Preferences for Implementation. International Journal of Neonatal Screening. 2024;10(1).
Khorshidi HA, Marshall D, Goranitis I, Schroeder B, Ijzerman M. System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model. Expert Review of Pharmacoeconomics and Outcomes Research. 2024;24(1):37-47.
Mallett AJ, Ingles J, Goranitis I, Stark Z. Implementation of reimbursement for genomic testing in Australia: early successes and the pathway ahead. Internal Medicine Journal. 2024;54(4):531-4.
Wu Y, Jayasinghe K, Stark Z, Quinlan C, Patel C, McCarthy H, et al. Response to Lombardi and Mesnard. Genetics in Medicine. 2024;26(1).
Jayasinghe K, Biros E, Harris T, Wood A, O'Shea R, Hill L, et al. Implementation and Evaluation of a National Multidisciplinary Kidney Genetics Clinic Network Over 10 Years. Kidney International Reports. 2024;9(8):2372-85.
2023
Santos Gonzalez F, Mordaunt D, Stark Z, Dalziel K, Christodoulou J, Goranitis I. Microcosting diagnostic genomic sequencing: A systematic review. Genet Med. 2023 Mar 16;25(6):100829. doi: 10.1016/j.gim.2023.100829.
Lynch F, Meng Y, Best S, Goranitis I, Savulescu J, Gyngell C, Vears DF. Australian public perspectives on genomic data governance: responsibility, regulation, and logistical considerations. European Journal of Human Genetics. 2023 May 10. Doi: 10.1038/s41431-023-01381-
Robertson EG, Kelada L, Best S, Goranitis I, Pierce K, CoGENeS Group*, Bye A, Palmer EE . Quality of life in caregivers of a child with a developmental and epileptic encephalopathy. Dev Med Child Neurol. 2023 Jul 08; 00:1– 10. Doi: https://doi.org/10.1111/dmcn.15695
Mordaunt DA, Dalziel K, Goranitis I, Stark Z. Uptake of funded genomic testing for syndromic and non-syndromic intellectual disability in Australia. European Journal of Human Genetics. 2023 July 03. Doi: https://doi.org/10.1038/s41431-023-01417-6
McLoughlin C, Goranitis I, Al Janabi H. The feasibility and validity of preference-based quality of life measures with informal carers: a think-alouid study. Vallue in Health. 2023 Jul 27. Doi: https://doi.org/10.1016/j.jval.2023.07.002
Sheen D, Peasgood T, Goranitis I. Eliciting Societal Preferences for Non-Health Outcomes: A Person Trade-Off Study in the COntext of Genomics. Clinical Therapeutics. 2023 Jul 29. Doi: https://doi.org/10.1016/j.clinthera.2023.07.004
Wu Y, Jayasinghe K, Stark Z, Quinlan C, Patel C, McCarthy H, Mallawaarachchi AC, Mallett AJ, Goranitis I. Genomic testing for suspected monogenic kidney disease in children and adults: a health economic evaluation. Genetics in Medicine. 2023 Jul 21. Doi: https://doi.org/10.1016/j.gim.2023.100942
Khorshidi, H. A., Marshall, D., Goranitis, I., Schroeder, B. & Ijzerman, M. (2024). System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 24(1), pp. 37-47. doi:10.1080/14737167.2023.2267764
Robertson, E. G., Roberts, N. J., Le Marne, F., Beavis, E., ...Goranitis I.,... Palmer, E. E. (2023). "Somewhere to turn to with my questions": A pre-post pilot of an information linker service for caregivers who have a child with a Developmental and Epileptic Encephalopathy. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 47 pp. 94-104. doi:10.1016/j.ejpn.2023.09.010
Mallett A, Stark Z, Fehlberg Z, Best S, Goranitis I. Determining the utility of diagnostic genomics: a conceptual framework. Human Genomics. 2023 Aug 16. Doi: https://doi.org/10.1186/s40246-023-00524-1
Mordaunt DA, Stark Z, Santos Gonzalez F, Dalziel, K, Goranitis I. Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia BMJ Open 2023;13:e069441. doi: 10.1136/bmjopen-2022-069441
Pan, T Wu Y, Buchanan J, Goranitis I. QALYs and rare diseases: exploring the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing for childhood and adult-onset rare genetic conditions in Australia. Health Qual Life Outcomes. 2023. 21, 132. https://doi.org/10.1186/s12955-023-02216-9
Zhou Y, Shadbolt C, Thuraisingam S, Schilling C, Choong P, Dowsey M Differences in Outcomes Between Initial Responders and Subsequent Responders to Health Questionnaires for Total Hip and Knee Arthroplasty: An Australian Tertiary Institutional Registry Study. JOURNAL OF ARTHROPLASTY. 2023; 38(12): 2561-2567. doi:10.1016/j.arth.2023.05.079
Zhou Y, Frampton C, Dowsey M, Choong P, Schilling C, Hirner M Assessing the Mortality Rate After Primary Total Knee Arthroplasty: An Observational Study to Inform Future Economic Analysis. JOURNAL OF ARTHROPLASTY. 2023; 38(11): 11-. doi:10.1016/j.arth.2023.05.070
Schilling C, Tew M, Bunzli S, Shadbolt C, Lohmander L, Balogh Z, Paolucci F, Choong P, Dowsey M, Clarke P An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials. APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2023; 21(2): 263-273. doi:10.1007/s40258-022-00775-4
Zhou Y, Dowsey M, Spelman T, Choong P, Schilling C DEVELOPING AND EVALUATING THE SMART CHOICE (KNEE): A PATIENT-FOCUSED TOOL TO PREDICT HEALTH-RELATED QUALITY OF LIFE OUTCOMES AFTER TOTAL KNEE ARTHROPLASTY. Orthopaedic Proceedings. 2023; 105-B(SUPP_3): 118-118. doi:10.1302/1358-992x.2023.3.118
Zhou Y, Shadbolt C, Rele S, Spelman T, Dowsey M, Choong P, Schilling C CALCULATING AND COMPARING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE FOR VETERANS RAND 12 UTILITY SCORE IN TOTAL KNEE ARTHROPLASTY. Orthopaedic Proceedings. 2023; 105-B(SUPP_3): 117-117. doi:10.1302/1358-992x.2023.3.117
Kuek T, Schilling C, Choong P The impact of cost on quality of surgical management in non-metastatic extremity sarcoma: A cross-country narrative literature review with a systematic approach. JOURNAL OF ORTHOPAEDIC SURGERY. 2023; 31(1): 10-. doi:10.1177/10225536231168989
Gorniak M, Pardillo M, Keating C, Brown C, Schilling C Net cost savings arising from patient completion of an active self-management program.. PLoS One. 2023; 18(11): e0293352-. doi:10.1371/journal.pone.0293352
Peasgood T, Bourke M, Devlin N, Rowen D, Yang Y, Dalziel K Randomised comparison of online interviews versus face-to-face interviews to value health states. SOCIAL SCIENCE & MEDICINE. 2023; 323: 11-. doi:10.1016/j.socscimed.2023.115818
Xiong X, Huang L, Herd DW, et al. Cost-effectiveness of prednisolone to treat Bell Palsy in children: an economic evaluation alongside a randomized controlled trial. Neurology. 2023;100(24):e2432-e2441.
Xiong, X., Dalziel, K., Huang, L. et al. How do common conditions impact health-related quality of life for children? Providing guidance for validating pediatric preference-based measures. Health Qual Life Outcomes 21, 8 (2023). https://doi.org/10.1186/s12955-023-02091-4
Xiong X, Dalziel K, Huang L, Rivero-Arias O. Test-Retest Reliability of EQ-5D-Y-3L Best-Worst Scaling Choices of Adolescents and Adults,Value in Health,Volume 26, Issue 1,2023
Palladino R*, Pan T*, Mercer SW, Atun R, McPake B, Rubba F, Triassi M, Lee JT (2023). Multimorbidity and out-of-pocket expenditure on medicine in Europe: Longitudinal analysis of 13 European countries between 2013 and 2015. Front Public Health. 2023 Jan 5;10:1053515.1–12.
Zhang X, Pan T, McPake B (2023). Re-examining the reversal hypothesis: A nationwide population-based study of the association between socioeconomic status, and NCDs and risk factors in China. SSM - Population Health, 21, 2023, 101335, 1–12.
Ishida, M., D’Souza, M., Zhao, Y., Pan, T., Carman, W., Haregu, T., Lee, TJ (2023). The association between obesity, health service use, and work productivity in Australia- a cross-sectional quantile regression analysis. Sci Rep 13, 6696, 1–9. (2023).
Mulhern B, Pan T, Norman R, Tran-Duy A, Hanmer J, Viney R, Devlin N Understanding the measurement relationship between EQ-5D-5L, PROMIS-29 and PROPr. QUALITY OF LIFE RESEARCH. 2023; 32(11): 3147-3160. doi:10.1007/s11136-023-03462-6
Devlin N, Pan T, Sculpher M, Jit M, Stolk E, Rowen D, Van Hout B, Norman R Using Age-Specific Values for Pediatric HRQoL in a Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?. PHARMACOECONOMICS. 2023; 41(10): 1165-1174. doi:10.1007/s40273-023-01300-8
2022
Robertson E, Kelada L, Best S, Goranitis I, Grainger N, Le Marne F, Pierce K, Nevin S, Macintosh R, Beavis E, Sachdev R, et al. Acceptability and feasibility of an online information linker service for caregivers who have a child with genetic epilepsy: a mixed-method pilot study protocol. BMJ OPEN. 2022; 12(10): 10-. doi:10.1136/bmjopen-2022-063249
Buchanan J, Goranitis I, Slade I, Kerasidou A, Sheehan M, Sideri K, Wordsworth S Resource allocation in genetic and genomic medicine.. J Community Genet. 2022; 13(5): 463-466. doi:10.1007/s12687-022-00608-w
Goranitis I Health policy making under information constraints: An evaluation of the policy responses to the economic crisis in Greece (vol 117, pg 279, 2014). HEALTH POLICY. 2022; 126(7): 722-722.
Wu Y, Balasubramaniam S, Rius R, Thorburn D, Christodoulou J, Goranitis I Genomic sequencing for the diagnosis of childhood mitochondrial disorders: a health economic evaluation. EUROPEAN JOURNAL OF HUMAN GENETICS. 2022; 30(5): 577-586. doi:10.1038/s41431-021-00916-8
Goranitis I, Wu Y, Lunke S, White S, Tan T, Yeung A, Hunter M, Martyn M, Gaff C, Stark Z Is faster better? An economic evaluation of rapid and ultra-rapid genomic testing in critically ill infants and children. GENETICS IN MEDICINE. 2022; 24(5): 1037-1044. doi:10.1016/j.gim.2022.01.013
Meng Y, Clarke P, Goranitis I The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions. Pharmacoeconomics. 2022; 40(2): doi:10.1007/s40273-021-01103-9
Datt G, Liu C, Smyth R Missing Women in China and India over Seven Decades: An Analysis of Birth and Mortality Data from 1950 to 2020. JOURNAL OF DEVELOPMENT STUDIES. 2022; 58(9): 1807-1830. doi:10.1080/00220388.2022.2055466
Mar V, Liu W, Liu C, Mcarthur G, Wolfe R, Kelly J Growth Rate and Survival; the Insidious Progression of BRAF Mutant Melanomas. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2013; 11: 11-11.
Xiong, X., Dalziel, K., Carvalho, N. et al. Association between 24-hour movement behaviors and health-related quality of life in children. Qual Life Res 31, 231–240 (2022). https://doi.org/10.1007/s11136-021-02901-6
Pan, T., Anindya, K., Devlin, N. et al (2022). The impact of depression and physical multimorbidity on health-related quality of life in China: a national longitudinal quantile regression study Sci Rep. 12, 21620, 1–9 (2022).
Devlin, N., Pan, T., Kreimeier, S., Verstraete, J., Stolk, E., Rand, K., Herdman, M (2022). Health Qual Life Outcomes. 20, 105, 1–11 (2022).
Pan, T., Mulhern, B., Viney, R., Norman, R., Hanmer, J., Devlin, N. (2022). A comparison of PROPr and EQ-5D-5L value sets. PharmacoEconomics. 40, 297–307 (2022).
O’Loughlin R, Hiscock H, Pan T, Devlin N, Dalziel K. The relationship between physical and mental health multimorbidity and children’s health-related quality of life. (2022). Qual Life Res. 31, 2119–2131 (2022).
Pan, T., Mulhern, B., Viney, R., Norman, R., Tran-Duy, A., Hanmer, J., Devlin, N. (2022). Evidence on the relationship between PROMIS-29 and EQ-5D: A Literature Review. Qual Life Res. 31, 79–89. (2022).
2021 and earlier
Bunzli S, Choong E, Shadbolt C, Wall L, Nelson E, Schilling C, Wilding H, Lohmander L, Balogh Z, Paolucci F, Clarke P, et al. Placebo Surgery Controlled Trials Do They Achieve What They Set Out To Do? A Systematic Review. ANNALS OF SURGERY. 2021; 273(6): 1102-1107. doi:10.1097/SLA.0000000000004719
Bunzli S, Nelson E, Wall L, Schilling C, Lohmander L, Balogh Z, Tran P, Paolucci F, Clarke P, Choong P, Dowsey M, et al. Factors Underlying Patient and Surgeon Willingness to Participate in a Placebo Surgery Controlled trial: A Qualitative Investigation.. Ann Surg Open. 2021; 2(4): e104-. doi:10.1097/AS9.0000000000000104
Baker D, Dennis M, Zannino D, Schilling C, Moreno P, Bullock A, Disney P, Radford D, Hornung T, Grigg L, D'Udekem Y, et al. Path ahead for 'low risk' adolescents living with a Fontan circulation. HEART. 2021; 107(7): 556-+. doi:10.1136/heartjnl-2020-317619
Butterworth P, De New S, Schilling C, Saxby K, Petrie D, Wong C Dynamics of Mental Health and Healthcare Use among Children and Young Adults. AUSTRALIAN ECONOMIC REVIEW. 2021; 54(1): 130-146. doi:10.1111/1467-8462.12413
Rele S, Shadbolt C, Schilling C, Taylor N, Dowsey M, Choong P The Impact of Enhanced Recovery After Surgery on Total Joint Arthroplasty: Protocol for a Systematic Review and Meta-analysis. JMIR RESEARCH PROTOCOLS. 2021; 10(3): 8-. doi:10.2196/25581
Trieu J, Schilling C, Dowsey M, Choong P The cost-effectiveness of computer navigation in primary total knee replacement: a scoping review. EFORT OPEN REVIEWS. 2021; 6(3): 173-180. doi:10.1302/2058-5241.6.200073
Anindya K, Ng N, Atun R, Marthias T, Zhao Y, Mcpake B, Van Heusden A, Pan T, Lee J Effect of multimorbidity on utilisation and out-of-pocket expenditure in Indonesia: quantile regression analysis. BMC HEALTH SERVICES RESEARCH. 2021; 21(1): 12-. doi:10.1186/s12913-021-06446-9
Pan T, Mercer S, Zhao Y, Mcpake B, Desloge A, Atun R, Hulse E, Lee J The association between mental-physical multimorbidity and disability, work productivity, and social participation in China: a panel data analysis. BMC PUBLIC HEALTH. 2021; 21(1): 13-. doi:10.1186/s12889-021-10414-7
Zhao Y, Atun R, Anindya K, Mcpake B, Marthias T, Pan T, Van Heusden A, Zhang P, Duolikun N, Lee J Medical costs and out-of-pocket expenditures associated with multimorbidity in China: quantile regression analysis. BMJ GLOBAL HEALTH. 2021; 6(2): 10-. doi:10.1136/bmjgh-2020-004042
Goranitis I, Best S, Christodoulou J, Boughtwood T, Stark Z Preferences and values for rapid genomic testing in critically ill infants and children: a discrete choice experiment. EUROPEAN JOURNAL OF HUMAN GENETICS. 2021; 29(11): 1645-1653. doi:10.1038/s41431-021-00874-1
Jayasinghe K, Wu Y, Stark Z, Kerr P, Mallett A, Gaff C, Martyn M, Goranitis I, Quinlan C Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases. KIDNEY INTERNATIONAL REPORTS. 2021; 6(11): 2850-2861. doi:10.1016/j.ekir.2021.08.028
Goranitis I, Best S, Stark Z, Boughtwood T, Christodoulou J The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment. GENETICS IN MEDICINE. 2021; 23(1): 155-162. doi:10.1038/s41436-020-00949-2
Hall J, Goranitis I, Kigozi J, Guariglia A New evidence on the impact of the Great Recession on health-compromising behaviours. ECONOMICS & HUMAN BIOLOGY. 2021; 41: 9-. doi:10.1016/j.ehb.2021.100980